Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon

Abstract excerpt

In previous studies on localized GISTs, KIT exon 11 deletions and mutations involving codons 557/558 showed an adverse prognostic influence on recurrence-free survival. In the metastatic setting, there are limited data on how mutation type and codon location might contribute to progression-free survival (PFS) variability to first-line imatinib treatment. We analyzed the type and gene location of KIT and PDGFRA...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastric Cancer Management and Outcomes
• Share to Gastrointestinal disorders and treatments
• Share to Gastrointestinal Tumor Research and Treatment